临床遗传学中的风险是什么? 设计和试点工具来评估临床遗传学中的风险,使用故障模式和效应分析分析
Deborah M Lambert1,2, Helen Stewart3, Mari Bandiola3
1University College Dublin, Belfield, Dublin, Republic of Ireland. dlambert@rotunda.ie.
European journal of human genetics : EJHG
|October 28, 2025
概括
临床遗传学缺乏系统风险工具. 在欧洲各地开发和试验了新的方法,显示了>3%的不良事件,并确定了改善患者安全的关键失败点.
科学领域:
- 医学遗传学 医学遗传学
- 医疗保健服务研究 医疗服务研究
- 患者安全 患者安全
背景情况:
- 风险管理在医疗保健中至关重要,但在临床遗传学中缺乏系统方法.
- 现有的风险评估方法并不适合临床遗传学服务的具体需求.
研究的目的:
- 开发和验证临床遗传学特定的风险评估工具.
- 为了前性地监测风险,并使风险降低控制的实施.
主要方法:
- 在爱尔兰临床遗传学中对115个不良事件/近乎事故的回顾性审查.
- 开发患者旅程过程图和临床审计表格.
- 在6个欧洲中心试点和重新审计工具,调整国家风险评分.
主要成果:
- 在6个中心中的4个中,不良事件超过了约会的3% (范围为0.8-20.3%).
- 常见的失败模式包括同意,样本处理和患者讨论,因中心而异.
- 重新审计表明,这些工具在反映引入的干预措施方面具有实用性.
结论:
- 开发的工具与故障模式和效应分析保持一致,为临床遗传学中的风险评估提供了一种标准化的方法.
- 这些工具可以前性地监测不良事件,促进风险降低和提高服务质量.
更多相关视频
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
11.3K
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
34.6K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
397
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
397
Hazard Rate
399
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
399
Genetic Screens
5.6K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.6K
Mutagenicity and Carcinogenicity
1.9K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K
Fatigue
792
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
792
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
